NASDAQ:TRPXTHERAPIX BIOSCI/S Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding THERAPIX BIOSCI/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.32 0.00 (0.00 %) (As of 07/16/2020) Add Compare Share Today's Range$0.32Now: $0.32▼$0.3250-Day Range$0.32MA: $0.44▼$0.7652-Week Range$0.25Now: $0.32▼$4.69VolumeN/AAverage VolumeN/AMarket Capitalization$1.11 millionP/E RatioN/ADividend YieldN/ABeta0.27 ProfileAdvanced ChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110 for the treatment of Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 for the treatment of Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain. Therapix Biosciences Ltd. has a product development agreement with Cure Pharmaceutical to develop cannabinoid-based product for sleep disorders. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Givatayim, Israel.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for THERAPIX BIOSCI/S. Previous Next 2.6 Community Rank Outperform VotesTHERAPIX BIOSCI/S has received 226 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTHERAPIX BIOSCI/S has received 211 “underperform” votes. (Add your “underperform” vote.)Community SentimentTHERAPIX BIOSCI/S has received 51.72% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about THERAPIX BIOSCI/S and other stocks. Vote “Outperform” if you believe TRPX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TRPX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldTHERAPIX BIOSCI/S does not currently pay a dividend.Dividend GrowthTHERAPIX BIOSCI/S does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, THERAPIX BIOSCI/S insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 1.07% of the stock of THERAPIX BIOSCI/S is held by institutions. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.52 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TRPX Previous Symbol CUSIPN/A CIK1611746 Webtherapixbio.com Phone972-3616-7055Debt Debt-to-Equity Ratio6.71 Current Ratio0.91 Quick Ratio0.91Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees9 Outstanding Shares3,510,000Market Cap$1.11 million Next Earnings DateN/A OptionableNot Optionable $0.32 0.00 (0.00 %) (As of 07/16/2020) 30 days | 90 days | 365 days | Advanced Chart Receive TRPX News and Ratings via Email Sign-up to receive the latest news and ratings for TRPX and its competitors with MarketBeat's FREE daily newsletter. THERAPIX BIOSCI/S (NASDAQ:TRPX) Frequently Asked Questions How has THERAPIX BIOSCI/S's stock been impacted by COVID-19 (Coronavirus)? THERAPIX BIOSCI/S's stock was trading at $0.45 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TRPX stock has decreased by 29.6% and is now trading at $0.3170. View which stocks have been most impacted by Coronavirus. How were THERAPIX BIOSCI/S's earnings last quarter? THERAPIX BIOSCI/S (NASDAQ:TRPX) announced its quarterly earnings results on Monday, August, 20th. The company reported ($0.35) EPS for the quarter, topping the Zacks' consensus estimate of ($0.59) by $0.24. View THERAPIX BIOSCI/S's earnings history. Has THERAPIX BIOSCI/S been receiving favorable news coverage? Media stories about TRPX stock have trended somewhat positive on Tuesday, InfoTrie Sentiment reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. THERAPIX BIOSCI/S earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View the latest news about THERAPIX BIOSCI/S. Who are some of THERAPIX BIOSCI/S's key competitors? Some companies that are related to THERAPIX BIOSCI/S include Sienna Biopharmaceuticals (SNNA), Innovus Pharmaceuticals (INNV), IntelliPharmaCeutics Intl (IPCIF), VIVUS (VVUS), MusclePharm (MSLP), Innovus Pharmaceuticals (INNVD), Wize Pharma (WIZP), Global Future City (FTCY), Parnell Pharmaceuticals (PARNF), Respirerx Pharmaceuticals (RSPI), Earth Science Tech (ETST), MOTIF BIO PLC/S (MTFB), Sienna Biopharmaceuticals (MLNTQ), Peak Pharmaceuticals (PKPH) and Boston Therapeutics (BTHE). View all competitors. What other stocks do shareholders of THERAPIX BIOSCI/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other THERAPIX BIOSCI/S investors own include Zynerba Pharmaceuticals (ZYNE), Cara Therapeutics (CARA), Canopy Growth (CGC), GW Pharmaceuticals PLC- (GWPH), 22nd Century Group (XXII), Sangamo Therapeutics (SGMO), Corbus Pharmaceuticals (CRBP), Cronos Group (CRON), Neptune Wellness Solutions (NEPT) and SCYNEXIS (SCYX). Who are THERAPIX BIOSCI/S's key executives? THERAPIX BIOSCI/S's management team includes the following people: Dr. Ascher Shmulewitz, Chairman & Interim CEO (Age 63)Dr. Adi Zuloff-Shani, Chief Technology Officer (Age 51)Mr. Oz Adler CPA, Chief Financial Officer (Age 32) What is THERAPIX BIOSCI/S's stock symbol? THERAPIX BIOSCI/S trades on the NASDAQ under the ticker symbol "TRPX." Who are THERAPIX BIOSCI/S's major shareholders? THERAPIX BIOSCI/S's stock is owned by a variety of institutional and retail investors. Top institutional investors include UBS Group AG (1.18%). Which institutional investors are buying THERAPIX BIOSCI/S stock? TRPX stock was bought by a variety of institutional investors in the last quarter, including UBS Group AG. How do I buy shares of THERAPIX BIOSCI/S? Shares of TRPX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is THERAPIX BIOSCI/S's stock price today? One share of TRPX stock can currently be purchased for approximately $0.32. How big of a company is THERAPIX BIOSCI/S? THERAPIX BIOSCI/S has a market capitalization of $1.11 million. THERAPIX BIOSCI/S employs 9 workers across the globe. What is THERAPIX BIOSCI/S's official website? The official website for THERAPIX BIOSCI/S is therapixbio.com. How can I contact THERAPIX BIOSCI/S? THERAPIX BIOSCI/S's mailing address is 4 ARIEL SHARON STREET HASHAHAR TOWER 16TH FLOOR, GIVATAYIM L3, 5320047. The company can be reached via phone at 972-3616-7055 or via email at [email protected] This page was last updated on 8/4/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
